Clinical trial
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid…
NCT00062075 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00062075 |
|---|---|
| Title | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Official title | A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8 and 3 more |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 47 |
| Start date | May 1, 2003 |
| Primary completion | Mar 1, 2007 |
| First posted | Jun 6, 2003 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: